Singapore
· Delayed Price · Currency is SGD Biolidics Statistics
Total Valuation
Biolidics has a market cap or net worth of SGD 7.75 million. The enterprise value is 8.87 million.
| Market Cap | 7.75M |
| Enterprise Value | 8.87M |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biolidics has 774.76 million shares outstanding. The number of shares has increased by 67.09% in one year.
| Shares Outstanding | 774.76M |
| Shares Change (YoY) | +67.09% |
| Shares Change (QoQ) | -6.30% |
| Owned by Insiders (%) | 35.93% |
| Owned by Institutions (%) | 6.23% |
| Float | 477.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.44 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.97 |
| EV / Sales | 6.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.17
| Current Ratio | 0.17 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -40.42 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -91.01% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 85,067 |
| Profits Per Employee | -199,000 |
| Employee Count | 15 |
| Asset Turnover | 0.63 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -28.57% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 50.46 |
| Average Volume (20 Days) | 1,435,015 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biolidics had revenue of SGD 1.28 million and -2.99 million in losses. Loss per share was -0.00.
| Revenue | 1.28M |
| Gross Profit | 566,000 |
| Operating Income | -2.95M |
| Pretax Income | -2.91M |
| Net Income | -2.99M |
| EBITDA | -2.94M |
| EBIT | -2.95M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 150,000 in cash and 1.27 million in debt, giving a net cash position of -1.12 million or -0.00 per share.
| Cash & Cash Equivalents | 150,000 |
| Total Debt | 1.27M |
| Net Cash | -1.12M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -2.39M |
| Book Value Per Share | -0.00 |
| Working Capital | -2.27M |
Cash Flow
| Operating Cash Flow | -1.34M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 44.36%, with operating and profit margins of -231.27% and -233.93%.
| Gross Margin | 44.36% |
| Operating Margin | -231.27% |
| Pretax Margin | -228.21% |
| Profit Margin | -233.93% |
| EBITDA Margin | -230.64% |
| EBIT Margin | -231.27% |
| FCF Margin | n/a |
Dividends & Yields
Biolidics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -67.09% |
| Shareholder Yield | -67.09% |
| Earnings Yield | -43.06% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |